Background {#Sec1}
==========

Antimicrobial resistance (AMR) is a cause for global concern due to the current and potential impact on global population health, costs to healthcare systems and Gross Domestic Product (GDP), mainly through reduced treatment options \[[@CR1]\]. Recent reports suggest that absolute numbers of infections due to resistant microbes are increasing globally \[[@CR2]--[@CR4]\]. Estimates of the potential economic burden of AMR from recent reports, such as 'The Review on Antimicrobial Resistance' \[[@CR1]\], are being utilised by policy makers to push AMR up the political agenda \[[@CR5]\]. However, more precise estimates of AMR burden are needed to inform policy through health economic models evaluating interventions attempting to prevent, treat or stop the spread of resistant infections \[[@CR6], [@CR7]\].

In order to establish burden, the perspective being taken should be defined. The patient perspective refers to associated mortality and morbidity (including clinical outcomes), while the payer perspective can include attributable costs to the payers of healthcare including insurers or national payers \[[@CR6]\]. The provider perspective estimates the burden to certain providers of healthcare, such as hospitals and primary care practices \[[@CR6]\]. In cases where there is national/governmental provision and payment of healthcare services, the provider and payer perspectives may align to be the same, such as in the case of the National Health Service and the Department of Health in England \[[@CR6]\]. The economic (or societal) perspective generally includes the potential impact on the labour force through lost productivity \[[@CR8], [@CR9]\], but can also include the burden on carers and patient out-of-pocket expenses \[[@CR10], [@CR11]\]. AMR may also create burden through secondary effects, referred to in this review as secondary burden. Secondary patient burden, and onward effects to healthcare system or society, occurs when procedures that utilise antimicrobials to reduce the risk of post-intervention adverse events (such as surgical procedures utilising prophylactic antibiotics) are performed less frequently due to AMR increasing the risk of adverse events \[[@CR12]\].

The different perspectives of burden produce varying outcome measures. For example, from a patient perspective an excess mortality figure may be determined \[[@CR13]\], whilst looking from a payer or provider perspective could produce an excess cost of hospital treatment in monetary terms \[[@CR14]\], and economic burden could refer to excess GDP losses for a country \[[@CR15]\]. Obtaining estimates for these different outcomes, may require different methodologies, ranging from case-control studies with regression analyses to complex mathematical and economic models \[[@CR16], [@CR17]\].

Past descriptive review articles have discussed the methods of estimating the burden of AMR \[[@CR9], [@CR18], [@CR19]\]. However, since an update in 2012 of a previous systematic review \[[@CR8], [@CR20]\], there has been no formal systematic assessment of the methods used in AMR burden estimation, or the variation in resulting outcomes. The 2012 update concluded economic evidence was lacking, and that over the 21 studies included there were large variations in the estimates of AMR burden \[[@CR8]\]. However, there been no formal quality assessment of recent AMR burden evidence across the stated perspectives, which is needed when discussing study methodology and its limitations. Given the growing media coverage of and policy interest in AMR over recent years \[[@CR21], [@CR22]\], there has been a corresponding marked increase in the published evidence on AMR impact. As such, this review aimed to capture and assess this recent portion of the literature, by reviewing the evidence published since the review in 2012 by Smith and Coast \[[@CR8]\]. This review aimed to capture both the burden in the sense of the incremental impact of resistance (in addition to infection) and the burden of resistant infections among all of the population. Therefore this systematic review aimed to address the following research questions in regards to the human population, with no limitation on microbe of interest; (i) what perspectives and resulting methodologies have been used to estimate AMR burden in the recent published literature? (ii) Do AMR burden estimates differ by perspective and methodology? (iii) What is the quality of this recent evidence on the burden of AMR?

Methods {#Sec2}
=======

This Systematic review is in line with PRISMA guidance, is registered with PROSPERO (registration number PROSPERO CRD42016037510) and has a previously published protocol \[[@CR23]--[@CR25]\].

Search strategy and eligibility criteria {#Sec3}
----------------------------------------

Studies which aimed to quantify the burden of AMR (in humans) published since the Smith and Coast review in 2012 \[[@CR8]\] were of interest, and as such, the search was limited from January 2013 -- December 2015. Ovid 'Medline & EMBASE', Scopus and EconLit were searched utilising a search string, which employed combinations of the following terms; excess, associated, attributable, burden, morbidity, mortality, cost, economic, clinical, global, impact, outcome, burden, antibiotic, antimicrobial, multi-drug, microbial-drug, resistan\*, gram-positive, gram-negative, susceptib\*,nonsusceptib\*, enterococc\*, Escherichia, streptococc\*, staphylococc\*, klebsiealla, pseudomonas, neisseria, chlamydia, clostridi\*, mycobacteri\*. In deviation to the published protocol \[[@CR25]\], an additional search of PubMed was conducted for literature published within the stated time period, whereby titles were searched using the following string; "(((((mortality\[Title\]) OR cost\[Title\]) OR length of stay\[Title\]) OR productivity\[Title\]) AND resistant\[Title\]) AND infection\*\[Title\]" \[[@CR26]\]. The following websites were also searched for grey literature: Public Health England, Public Health Wales, Health Protection Scotland, NHS Health Scotland, Department of Health (UK), Health Protection Agency, National Institute for Health and Care Excellence, Centers for Disease Control and Prevention, World Health Organisation, European Commission for Public Health, Review on Antimicrobial Resistance.

The modified PICO inclusion/exclusion criteria (Table [1](#Tab1){ref-type="table"}) were utilised to screen title/abstracts and subsequently full-texts \[[@CR27]\].Table 1Inclusion/Exclusion Criteria Applied \[[@CR25]\]CriteriaInclusionExclusionPopulationHumansAnimals onlyAll agesPlants onlyAll sexesInfection with antimicrobial resistant organism (or similar such as Extended Spectrum Beta-lactamase producing organisms). This includes future predictions of related infected populations, such as in the case of a "post-antibiotic" eraOutcomesAssociated health burden, including mortality and morbidityHealth-Related Quality of Life onlyAssociated healthcare cost burden, including resource use and opportunity costMolecular biology onlyEconomic burden, including loss of productivityEpidemiology onlyBurden from not being able to use antibiotics in ways previously or currently used in healthcare, including reduced surgery or chemotherapyOutcomes associated with the evaluation of an intervention onlyStudy designCase--control studiesEditorialsCohort studiesLettersCross--sectional studiesCase series reportsLongitudinal studiesConference reportsRandomised controlled trialsEvaluations of interventionsModelling studiesReviewsEconomic Evaluations

Data extraction and quality assessment {#Sec4}
--------------------------------------

Data were extracted from each study into a Data Extraction Table using Microsoft Excel. The following variables were collected as part of this process; study identifier, perspective, infection of interest (exposure, non-exposure, case and control definitions), outcome, country setting, study population, study design, data setting, epidemiological scope, method, sample size, (resistance-related) result, stated limitations and quality (risk of bias).

To establish what perspectives and resulting methodologies have been used in establishing AMR burden, study perspectives were grouped into either patient, healthcare system (representing payer and/or provider perspectives) or economic/societal burden. Studies estimating the secondary effects of AMR can do so by estimating the potential impact on health (such as excess deaths), healthcare system or economic burden (excess cost), so could be marked under each of these perspectives. Study methodologies were grouped into the following categories; regression analysis (parametric regression models), survival analysis (this included semi-parametric Cox proportional hazard models and non-parametric time to event analysis), matching, multistate models (including decision trees), economic models (including total factor or computable general equilibrium models), stepwise calculations (for example synthesising evidence from the literature and applying simple calculations to arrive at an estimate), significance tests and other (if none of the former categories applied).

The outcome of particular interest for patient burden was mortality, using odds ratio (OR) and hazard ratio (HR) measures. In this review, length of stay (LoS), alongside monetary cost, was recorded as a healthcare system burden outcome, as it has been shown that for healthcare associated infections LoS is a major contributing factor to hospital costs \[[@CR28]\]. For economic burden, monetary cost was considered the main outcome of interest, however reporting of productivity, GDP and other such economic measures were also recorded. Impact significance was defined by *p* values (less than 0.05) and 95% confidence intervals (CIs), where appropriate.

Risk of bias within individual studies was assessed using the Newcastle-Ottawa scales for cohort and case-control studies \[[@CR29]\]. For this review a case-control study was defined when outcomes of interest (such death) were used to select the case and control groups, whereas cohort studies selected cases based on exposure to resistance \[[@CR30]\]. The Newcastle-Ottawa checklists include four domains of quality and eight possible stars \[[@CR29]\]. The Philips checklist was used for modelling studies, which includes three domains of quality and 57 possible stars \[[@CR31]\]. A quality score was derived as the proportion of applicable checklist stars achieved (zero and one representing no checklist items achieved and all checklist items achieved respectively), please see Additional file [1](#MOESM1){ref-type="media"}: Tables S1, S2 and S3 for the full checklists utilised.

Risk of bias across the evidence was presented using the median and interquartile ranges of the quality score by perspective. This was a deviation in methodology from the published protocol, which proposed evaluating sign and significance of results \[[@CR25]\], and was chosen as any other summary figures would be flawed due to the high heterogeneity in infection of interest and outcome \[[@CR32]\].

Data analysis {#Sec5}
-------------

Due to study heterogeneity no meta-analyses were performed. Monetary costs found were converted into 2013 United States dollars (USD) by inflating the cost to 2013 original-currency estimates using annual inflation rates \[[@CR33], [@CR34]\], then converting this into USD utilising 2013 average exchange rates \[[@CR35]\].

Descriptive statistics (such as proportions of papers and average quality scores), tables and graphs to collate and present ORs, HRs, LoS and monetary cost were executed in Microsoft Excel and R version 3.3.2 using packages 'plyr', 'metafor' and 'ggplot2' \[[@CR36]--[@CR38]\].

Results {#Sec6}
=======

A total of 5187 unique titles and abstracts were retrieved over the specified search period. Applying the selection process resulted in a total of 214 studies being included in the final review (Fig. [1](#Fig1){ref-type="fig"}). One hundred eighty-seven studies included a patient burden measure, 75 a healthcare system burden measure, and only 11 studies included an economic burden measure (Table [2](#Tab2){ref-type="table"}). The most individually studied genus was *Staphylococcus* (23%, 50/214), followed by *Klebsiella* (9%, 19/214) and *Acinetobacter* (8%, 18/214) respectively. The countries which individually produced the highest number of studies were the USA (19%, 40/214), followed by South Korea (7%, 15/214) and Spain (6%, 13/214). 64% of studies (138/214) used data from just one centre. The majority of studies (89%, 190/214) did not specify the epidemiological scope in estimating AMR burden, for example by stating whether relevant included infections were due to endemic- or outbreak-related microbes. See Additional file [1](#MOESM1){ref-type="media"}: Table S4 for individual study details.Fig. 1PRISMA Diagram of Article Retrieval & InclusionTable 2Perspectives & Methods used to Estimate the Burden of Antimicrobial ResistancePatient % (*n* = 187)Healthcare System % (*n* = 75)Economic % (*n* = 11)Regression Analysis44.9%34.7%9.1%Survival Analysis20.9%9.3%0.0%Matching4.8%10.7%9.1%Multistate model2.1%6.7%27.3%Economic Model0.0%0.0%18.2%Significance Tests26.2%32.0%0.0%Stepwise calculation1.1%6.7%27.3%Qualitative0.0%0.0%9.1%Note that some studies included more than one burden perspective per study (for example a study reporting impact on mortality and costs would appear in multiple perspective categories)

Estimating the patient burden of AMR {#Sec7}
------------------------------------

For estimating the patient burden of AMR, regression analyses and significance tests were the most utilised methods (Table [2](#Tab2){ref-type="table"}). 95% (177/187) of studies estimating patient burden calculated mortality burden, with the remaining 5% (10/187) focusing on morbidity burden. Of those estimating a mortality burden, 48% (85/177) of studies found that AMR had a significant impact on mortality. Studies which aimed to estimate the impact of resistance on morbidity mainly focused on clinical outcomes such as clinical failure, time to stability, recurring infections or development of secondary infections \[[@CR39]--[@CR47]\].

The majority of studies that utilised standard regression techniques to estimate ORs of a mortality event found resistance to be associated with higher mortality (Fig. [2a](#Fig2){ref-type="fig"} and Fig. [2b](#Fig2){ref-type="fig"}). Focusing on those which directly compared resistant and susceptible infections explicitly, 50% (7/14) and 47% (9/19) of the studies for Gram-positive and Gram-negative exposures, respectively, had 95% confidence intervals which crossed this OR = 1 threshold. This suggests non-statistical significance of such results. Across Gram-positive and Gram-negative infections, this occurred in 4/15 studies investigating resistant cases against "non-exposed" controls and in 2/8 studies investigating the burden of additional resistance mechanisms on already resistant infections (for example the impact of vancomycin resistance on Methicillin resistant *Staphylococcus aureus* (MRSA) patients).Fig. 2Odds ratios of Mortality Outcomes for Resistant Infections. Results presented are from studies utilising regression techniques, where 1.0 represents the point at which exposure does not affect the odds of the outcome occurring. The box point represents the reported OR value, with horizontal lines representing the reported 95% Confidence Interval. Results have not been adjusted or adapted to represent sample size, and are presented grouped by genera. **a** Gram-positive Bacteria. **b** Gram-negative Bacteria. \[[@CR16], [@CR56], [@CR59], [@CR61]--[@CR103]\]

Comparing Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} would suggest there is no clear consensus from either method (parametric regression or Cox proportional hazards regression) as to whether there is a significant impact of bacterial resistance mechanisms on mortality outcomes, though it should be noted that different measures of mortality have been used across these studies (see Additional file [1](#MOESM1){ref-type="media"}: Table S4). 32% (8/25) of these studies estimating mortality-related hazard ratios, did so in relation to in-hospital mortality. Such analysis may not accurately estimate the impact of exposure (versus non-exposure) on outcome, due to the failure of the non-informative censoring assumption, as the cause of being discharged may be related to the likelihood of experiencing death. As the infection type, resistance type and outcomes are different across the aforementioned studies a rigorous comparison cannot be made.Fig. 3Hazard Ratios of Mortality Outcomes for Resistant Infections. Results presented are from studies utilising Cox proportional hazards regression techniques, where 1.0 represents the point at which exposure and control experience the same event rate at any point in time. The box point represents the reported HR value, with horizontal lines representing the reported 95% Confidence Interval. Results have not been adjusted or adapted to represent sample size, and are presented grouped by genera. **a** Gram-positive Bacteria. **b** Gram-negative Bacteria. \[[@CR48], [@CR91], [@CR104]--[@CR121]\]

Only one study estimated the potential patient burden of AMR via secondary effects (secondary patient burden), by evaluating the impact on mortality (excess deaths) of reduced prophylactic antibiotic efficacy in the United States \[[@CR12]\]. Utilising an evidence synthesis and stepwise calculation approach, this study estimated that a 30% reduction in the efficacy of antibiotic prophylaxis for certain surgical and chemotherapeutic procedures would result in 6300 infection-related deaths annually \[[@CR12]\].

Estimating the healthcare system burden of AMR {#Sec8}
----------------------------------------------

For estimating the healthcare system burden (which incorporates the payer and provider perspectives) of AMR, regression analyses and significance tests were the most utilised methods. Seventy-five studies estimated healthcare system burden, 64 of these estimated LoS burden due to AMR and 31 estimated monetary cost (with some studies estimating both). The majority of studies evaluating LoS (69%, 44/64) found that resistance had a statistically significant impact, however 39% (17/44) of these utilised significance testing against descriptive statistics (such as median length of stay). Thirteen studies estimated excess LoS due to resistant infections (Fig. [4](#Fig4){ref-type="fig"}), with 3 studies using a multistate modelling methodology to estimate LoS. Multistate models attempt to adjust for time dependency bias \[[@CR48]--[@CR50]\], however this bias has also been adjusted for in other ways, such as shifting forward the index date from the date of hospital admission to the first day of the second calendar month of the patient's stay \[[@CR51]\]. The majority of excess LoS estimates were for Gram-positive bacteria, with only two estimates for a Gram-negative bacteria (Fig. [4](#Fig4){ref-type="fig"}). Excess LoS was estimated at 12.8 days for MRSA bloodstream infections \[95% CI 6.2 - 26.1 days\] \[[@CR48]\] in Australia, 11.5 \[95% CI: 7.9-15\] days for MRSA in Switzerland \[[@CR49]\] and 11.43 \[95% CI; 10.44 -- 12.43\] days for MRSA in American Veterans, utilising time dependency adjusted methods described above \[[@CR50]\]. These are similar to those computed by regression but much higher than that estimated by stepwise calculations (Fig. [4](#Fig4){ref-type="fig"}), though all are from different populations.Fig. 4Estimates of Excess Length of Stay of Hospital/ICU Stay Caused by Antimicrobial Resistance. (i) - (iii) denote different methods used in a single study \[[@CR48]--[@CR51], [@CR58], [@CR59], [@CR76], [@CR122], [@CR123], [@CR132] ,[@CR133]\]

A variety of methods have been used to calculate healthcare system monetary costs, with no clear majority of one method seen (Table [3](#Tab3){ref-type="table"}). After conversion to 2013 USD for comparing excess/attributable costs, for Extended-Spectrum beta-Lactamase (ESBL) in bloodstream infections, a matching study found no significant impact on healthcare system costs \[[@CR52]\], whilst a multistate model found an associated \$10,154 loss per case \[[@CR49]\]. For MRSA estimates ranged from non-significance \[[@CR53]\] to \$28,553 per case \[[@CR51]\] (across different populations for different infections, Table [3](#Tab3){ref-type="table"}).Table 3Excess Healthcare system Cost Estimates of Antimicrobial ResistanceStudyExposure GroupControl GroupCountryMethodExcess Cost Estimate (2013 USD)Cost per case \[[@CR109]\]CRAB in ColumbiaCarbapenem susceptible A. baumanniiColumbiaRegression4,583^a^ \[[@CR124]\]ESBL+ *E. coli* & Klebsiella species UTIESBL- *E. coli* & Klebsiella species UTIUSASignificance Tests3,237^a^ \[[@CR125]\]ESBL+ *E.coli* BSIESBL- *E.coli* BSIGermanyMatching-2081 \[[@CR49]\]ESBL+ *Enterobacteriaceae* BSIESBL- *Enterobacteriaceae* BSISwitzerlandMultistate model10,154 \[[@CR45]\]ESBL+ UTIESBL- UTISpainMatching & Regression3146† \[[@CR126]\]ESBL+ and/or beta-lactamases resistant UTISusceptible UTITurkeySignificance Tests90^a^ \[[@CR126]\]Ciprofloxacin resistant UTICiprofloxacin susceptible UTITurkeySignificance Tests114^a^ \[[@CR127]\]MDR *A. baumannii* BSISusceptible *A. baumannii* BSITurkeySignificance Tests15,365 \[[@CR58]\]MRSANon-exposure inpatientsGermanyStepwise Calculations11,878 \[[@CR53]\]MRSA breast abscessMSSA breast abscessUSAMatching515 \[[@CR128]\]MRSA BSINon-exposure BSISouth KoreaStepwise Calculations5216 \[[@CR129]\]MRSA BSI (survivors)Non-nosocomial-infected patientsSouth KoreaMatching11,627 \[[@CR129]\]MRSA BSI (non-survivors)Non-nosocomial-infected patientsSouth KoreaMatching15,254 \[[@CR51]\]MRSA infectionsNon-exposure inpatientsUSAMatching28,553^a^ \[[@CR130]\]MRSA colonisation & infectionNon-exposure inpatientsUSAMatching12,167^a^ \[[@CR131]\]Resistant BSISusceptible BSIIndiaSignificance Tests912^a^ \[[@CR132]\]Carbapenem-resistant device associated healthcare acquired infections ICU patientsNon-"device associated healthcare acquired infections" ICU patientsGreeceSignificance Tests3,884^a^ \[[@CR133]\]VRE colonisation & infectionsNon-exposure inpatientsCanadaMatching & Regression18,631^a^ \[[@CR76]\]VRE BSIVSE BSIAustraliaMatching & Regression30,093^a^ \[[@CR134]\]VRE BSI in allo-HSCT recipientsNon-exposure in allo-HSCT recipientsUSASignificance Tests6104 \[[@CR135]\]MDR TBNon-MDR TBGermanyStepwise Calculations86,321 \[[@CR136]\]MDR TBNon-MDR TBSouth AfricaStepwise Calculations6728 \[[@CR137]\]MDR TBNon-MDR TBLatviaRegression33291^a^ \[[@CR138]\]XDR and pre-XDR TBRifampicin-mono-resistant or MDR TBSouth AfricaStepwise Calculations15,567 \[[@CR136]\]XDR TBNon-"XDR or MDR" TBSouth AfricaStepwise Calculations26,989 \[[@CR139]\]VRE BSI in leukaemia patientsNon-exposure leukaemia patientsUSAMatching88150^a^Per-patient per-day \[[@CR50]\]MRSA in SwitzerlandNon-exposure inpatientsSwitzerlandMultistate model867 \[[@CR140]\]Resistant Gram-negative Bacilli infectionSusceptible Gram-negative Bacilli infectionSingaporeMatching812Annual cost per stated country or stated region \[[@CR57]\]MRSANo-MRSAUSAMultistate model1,382,733,079 \[[@CR141]\]Resistant Streptococcus pneumoniaSusceptible Streptococcus pneumoniaUSAMultistate model91,773,500 \[[@CR142]\]Artemisinin resistant malariaNo-"Artemisinin resistant malaria"High endemicity regionMultistate model32,000,000^a^Statistically significant where *p*-value is less than 0.05

Estimating the economic burden of AMR {#Sec9}
-------------------------------------

From the economic perspective stepwise calculations, multistate modelling and economic models were commonly used (Table [2](#Tab2){ref-type="table"}). Only a small number of studies were found in this perspective category, with 11 studies assessing the burden to the economy resulting from AMR. Eight of these reported an estimate for the monetary impact of resistance (Table [4](#Tab4){ref-type="table"}). In addition, two studies found investigated the potential psycho-social impact of having multi-drug resistant Tuberculosis, concluding that many patients in the qualitative study felt that multi-drug resistant Tuberculosis increased stigma and social isolation \[[@CR54]\], and increased the odds of incurring catastrophic costs (in which \[OR = 1.61 (95% CI = 0.98--2.64), *p* \< 0.06\]) \[[@CR43]\]. A report from 'The Review on Antimicrobial Resistance' did mention the secondary effects of AMR from the economic perspective, however did not attempt to quantify an exact figure for this, instead stating that some proportion of the 120 trillion USD gained from caesareans, joint operations, chemotherapy and organ transplants could be lost \[[@CR1]\].Table 4Excess Economic Burden Estimates of Antimicrobial ResistanceStudyExposure GroupControl GroupCountryMethodExcess Cost Estimate (2013 USD)Cost per case\[[@CR135]\]MDR TBSusceptible TBGermanyStepwise Calculation110,063\[[@CR135]\]XDR TBSusceptible TBGermanyStepwise Calculation145,679\[[@CR143]\]MDR TBSusceptible TBEuropeStepwise Calculation62,931\[[@CR143]\])XDR TBSusceptible TBEuropeStepwise Calculation215,038\[[@CR56]\]MRSA BSINon-nosocomial-infected patientsSouth KoreaMatching21,832Annual cost per stated country or stated region\[[@CR141]\]Resistant Streptococcus pneumoniaSusceptible Streptococcus pneumoniaUSAMultistate model236,495,000\[[@CR57]\]MRSANo MRSAUSAMultistate model7,848,223,600\[[@CR142]\]Artemisinin resistant malariaNo resistanceHigh endemicity regionsDecision Tree385,000,000Global economic cost\[[@CR15]\]Resistance globally (doubling of current infection rates and 100% resistance)Lower rates of resistance (a 40% resistance increase from current rates)GlobalTotal Factor Productivity model14,228,000,000 less GDP produced in 2050 compared to 2050 in a scenario with lower resistance\[[@CR55]\]Resistance globally (100% resistance rate)No resistanceGlobalComputable General Equilibrium model3,158,862,360 less GDP produced in 2050 compared to 2050 with no resistance

The only studies explicitly estimating the economic burden of AMR to include Gram-negative infections were those commissioned by 'The Review on Antimicrobial Resistance' (in which *Escherichia coli* and *Klebsiella pnuemoniae* were two out of six studied microbes) \[[@CR1], [@CR15], [@CR55]\]. These modelling studies, which utilised economic modelling techniques, provided the largest estimates of cost (though of six resistant microbes), estimating over \$14 billion to over \$3 trillion (2013 USD) in loss to global GDP by 2050 \[[@CR15], [@CR55]\]. Whilst the studies which utilised multistate modelling techniques (including decision tree analysis) or stepwise calculations, estimated national costs for a specific resistance type to range from over \$20,000 per MRSA bloodstream infection case to over \$7 billion per year attributable to community acquired MRSA in the United States (Table [4](#Tab4){ref-type="table"}) \[[@CR56], [@CR57]\].

### Quality of included studies {#Sec10}

For the outcomes and exposures tested relevant to this review, 199 studies were considered cohort, 1 case-control and 13 modelling studies, whereby the stated quality checklists were then applied. One additional study was a survey-based qualitative study and was not quality assessed \[[@CR54]\]. Median quality scores (with interquartile range (IQR)) for health, healthcare system and economic burden studies were 0.67 (0.56-0.67), 0.56 (0.46-0.67) and 0.53 (0.44-0.60) respectively. Within all perspectives, quality rarely exceeded 0.75. Notably there was a lack of economic burden studies and their median quality score was lower than that of the health and healthcare system studies (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Histograms of Quality Assessment Scores by Study Perspective

The Newcastle-Ottawa checklist criteria showed that only 54% of the total available points for adjustment/comparability of different exposure groups across all cohort studies were awarded (in all 199 studies, where two points were available per study \[[@CR29]\]), suggesting a need for more robust analyses estimating the impact of AMR. Some of the least fulfilled quality assessment categories by studies were those that focused on representativeness of the sample utilised (18% of the appraised studies met this criteria), description/adequacy of follow-up or non-response rates (40% met this criteria) and demonstration of non-exposure before study period (8% met this criteria), across the Newcastle-Ottawa cohort quality assessment checklist (199 studies).

For the 13 studies for which the Philips checklist was utilised to assess quality, there were many indicators for which scores were generally low, including those related to descriptions of the choice of model structure and the approach to obtaining parameter values (less than 1/3 of studies obtaining the related criteria). However, of note, none of the relevant studies met the following criteria; "Have the four principal types of uncertainty been addressed?", "If not, has the omission been justified?" and "Is there evidence that the mathematical logic of the model has been tested thoroughly before use?" \[[@CR31]\]. Additionally, only 23% of studies used a lifetime horizon or justified why they didn't use it and only 15% demonstrated a systematic approach to parameter selection.

**Box 1: Across Perspectives: A Tuberculosis Case Study** To illustrate the importance of clarifying the perspective chosen when investigating the burden of AMR, the case of multidrug resistant (MDR-) and extensively drug resistant (XDR-) Tuberculosis (TB) will be used, as studies of this infection-type provided cost estimates (monetary costs are 2013 USD) across perspectives (for full study details refer to Additional file [1](#MOESM1){ref-type="media"}: Table S4).**Patient burden:** In Peruvian adult patients, it was estimated that MDR-TB was significantly associated with mortality \[HR = 7.5 (95% CI; 4.1 -- 13.4)\] using regional network data \[[@CR144]\]. Likewise, in American patients, using data from a national institute, XDR was found to be significantly associated with mortality \[HR = 2.8 (95% CI; 1.4 -- 5.4)\] \[[@CR145]\]. In South African adult patients from one hospital, both MDR and XDR were associated with increased mortality \[MDR HR = 3.37, *p* \< 0.0001, and XDR HR = 6.75, *p* \< 0.001\] \[[@CR146]\]. All of the aforementioned studies looking into TB and mortality utilised a Cox proportional hazards approach. Another study utilised a Kaplan-Meier survival analysis methodology, and found that capromycin resistance in XDR TB was not significantly associated with mortality (*p* \< 0.0573) \[[@CR147]\]. Using Israeli patient data from a national registry, MDR was found to be significantly associated with TB-related death \[OR = 2.83(95% CI; 1.70-4.72), p \< 0.001\], using a logistic regression approach \[[@CR148]\].**Healthcare system burden:** MDR-TB was estimated to cost the South African healthcare system \$6728 excess per case, \$33,291 total per case in Latvia and \$86,321 total per case in Germany using an evidence synthesis approach \[[@CR135]--[@CR137]\]. These studies included factors such as length of stay, drug costs and services consumed (varying between studies).**Economic burden:** It was estimated, by evidence synthesis and stepwise calculation, that the total economic and societal burden costs per case for the original EU-15 states (i.e. healthcare system costs plus productivity loss, compared to susceptible TB) from MDR and XDR TB were \$62,931 and \$215,038 \[[@CR143]\]. MDR-TB was also found to be independently associated with incurring catastrophic costs in Peruvian patients older than 15 years \[OR = 1.61 (95% CI = 0.98--2.64)\], whereby catastrophic costs were defined as total costs greater than or equal to 20% of household annual income. Costs included direct medical and non-medical out-of-pocket costs (such as excess transport and food) \[[@CR43]\].

Discussion {#Sec11}
==========

The first aim of this review was to establish what perspectives and resulting methodologies have been used to estimate AMR burden in recent literature and to discern the impact this has on the actual estimates of burden. This review found that out of the 214 studies included, 187 studies provided an estimate of burden from the health perspective, 75 studies from the healthcare system perspective and 11 studies from the economic perspective. This review describes the large range of estimates that fall within these categories, and the methodologies used to obtain them. The most utilised methodologies were regression analysis for patient health and healthcare system burden calculations and either stepwise calculations or multistate models for economic burden estimates. An additional aim of this paper was to assess the quality of evidence for health, healthcare system and economic burden. There was a lack of economic burden studies, with the median quality score of these studies being lower than those of the health and healthcare system studies.

AMR is thought to potentially impact patient health through increasing patient mortality, though only around 50% of studies found a statistically significant impact when comparing resistant and susceptible infections. A substantial proportion of studies which used parametric regression or Cox proportional hazards techniques to estimate the impact of resistant infections in Gram-negative bacteria on mortality through OR or HR measures, had high uncertainty.

Evidence on additional length of hospital stay, a key driver of cost of infections in hospitals, was variable in terms of methodological choice and values found. A large proportion of the studies addressing length of stay in a healthcare facility did not explicitly state excess or associated length of stay, but rather estimated average length of stay for different groups and performed univariate comparisons of these averages. For those that did estimate excess length of stay, it was expected (given previous literature \[[@CR28]\]) that multistate model length of stay estimates compared to those found using alternative methods would be more conservative. However, this review found that multistate model estimates for length of stay for MRSA infection and MRSA bloodstream infection were higher than those using stepwise analysis and regression analysis \[[@CR48], [@CR50], [@CR58], [@CR59]\]. This is likely due to the fact that the described studies were set in different countries (Australia, Germany, Switzerland and US) and were mainly single centre studies, and so less externally valid. The use of multistate modelling methods to estimate attributable health and cost burden for resistant infections has previously been recommended because standard regression techniques may overstate the attributable length of stay for hospital onset infections, thus overestimating burden of AMR \[[@CR28], [@CR60]\]. However, we demonstrate that very few studies took advantage of this method over the search period.

Due to the small sample of economic burden studies, no consensus on method can be stated for estimating the economic burden, though 6 out of the 11 studies did utilise evidence synthesis and stepwise approaches or multistate models. The median quality of studies quantifying the economic burden of AMR fell below those of health and healthcare system burden studies, seemingly mainly due to a lack of rigorous, transparent modelling studies which appropriately present or incorporate uncertainty.

The recent reports produced by the 'The Review on Antimicrobial Resistance' attempted to address the lack of economic burden estimates in the field of AMR \[[@CR1], [@CR15], [@CR55]\]. However due to the large scope of these projects the models used provide only broad, general estimates (such as the global economic burden of AMR in general) which may be unsuitable for cost-effectiveness or resource allocation models. The review itself calls for the estimates to be developed using more data-driven approaches \[[@CR1]\]. This type of analysis has also recently been called into question due to its lack of scientific scrutiny and transparency, questioning the methodology used \[[@CR7]\].

Based on the results of this study, focusing on the results of the quality assessment of included studies, the following actions are recommended for future research in AMR burden;Utilise data from a representative sample of the population of interest. If this is not achievable due to data limitations, create and publish a clearly defined protocol that can be utilised in other institutions. This will enable future meta-analyses to be conducted.Choose an appropriate methodology that takes into account potential confounding factors (such as patient comorbidities or age) and biases (such as time dependency bias, competing risks or non-informative censoring).Describe data collection, data cleaning, follow-up, response rates and/or censoring clearly, where appropriate.Estimate healthcare system and economic impact where possible.If performing a mathematical or economic model, clearly describe the reasons for the chosen model structure (for example by detailing a formal health economic reasoning, including for chosen time horizon) and methods of parameterisation (with structured or systematic methods preferred). In addition, it is important to discuss how methodological, structural, heterogeneity and parameter uncertainty has been addressed (or discuss why these were not addressed).

Smith and Coast reported that estimates ranged from less than \$15 to around \$50,000 for additional costs per patient per episode to about \$20 billion per year from the societal/economic perspective (converted to 2013 USD) \[[@CR8]\]. This review found the healthcare system excess costs ranged from just almost non-significance to over \$90 million per year, whilst economic costs ranged from just over \$100,000 per case to over \$3 trillion total GDP loss by 2050 (in 2013 USD). Adding to the 21 studies included in the Smith and Coast 2012 review, this review discusses the results from an additional 214 studies. This review encountered a similar result to that of Smith and Coast in terms of lack of indirect burden evidence \[[@CR8]\]. However this review did find additional evidence on the potential secondary effects of AMR, with studies estimating the potential secondary effect of AMR on health and economic burden \[[@CR1], [@CR12]\].

Strengths of this review include its rigorous systematic methodology and its use of accepted quality assessment scales to present the first systematic picture of the quality of recent AMR burden estimates. This is particularly important when establishing the current evidence, as previously published review studies in this area have either been commentary pieces or have not incorporated any quality assessment across all three perspectives \[[@CR8], [@CR9], [@CR18]\]. One limitation of this study is that is has a relatively short search time period. This was chosen to build upon rather than duplicate the evidence produced within a previous review, and to capture recent evidence \[[@CR8]\]. Other limitations of the review include that the Health Related Quality of Life was not included as an outcome of interest. This was beyond the scope of this review given the very different methodologies applied in order to estimate Health Related Quality of Life burden, and that the majority of discussion of patient burden currently surrounds mortality impact.

Conclusion {#Sec12}
==========

This study concludes that perspective affects chosen methodology and outcome for quantifying the burden of AMR. The review finds substantially more research in patient burden and seemingly more of a consensus on the most appropriate methods to use (regression or survival techniques), in comparison to healthcare system and economic burden research. However, across patient and healthcare system burden studies, a worryingly high number of studies are utilising univariate statistical significance tests, suggesting that a high proportion of this evidence is unreliable. The review also concludes that the evidence on the economic burden of AMR is not substantial, whereby the majority of studies have not used established health economic modelling techniques or adhered well to the Philip's checklist \[[@CR31]\]. More evidence on the secondary effect of AMR on health, healthcare system and economic burden is also needed \[[@CR1], [@CR12]\].

The estimates presented in this review can be used as parameter inputs in future health economics models used to inform health policy, whilst the description of previous methods used can inform future researchers' methodology choice (based on their desired perspective). The review also highlights key areas where research is needed, including multivariate, internally and externally valid health and healthcare system burden studies. This research is needed particularly for Gram-negative bacteria. Additionally, high quality economic burden and secondary burden research is needed in general. Future AMR burden research should follow the recommendations highlighted in this review, in order to increase the quality of evidence available.
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3GCR

:   Third-generation cephalosporin resistant

*A. baumannii*

:   *Acinetobacter baumannii*

AC

:   Amoxicilline-clavulanate

Allo-HSCT

:   Allogeneic hematopoietic stem cell transplantation

AMR

:   Antimicrobial Resistance

BIVR

:   Beta-lactam induced vancomycin resistance

BSI

:   Bloodstream infection

CR

:   Carbapenem resistant

CRAB

:   Carbapenem-resistant *Acinetobacter baumannii*

CRKP

:   Carbapenem-resistant *Klebsiella pneumoniae*

*E. coli*

:   *Escherichia coli*

ESBL

:   Extended Spectrum Beta-lactamase

EUR

:   Euro

GDP

:   Gross Domestic Product

GN

:   Gram-negative

HR

:   Hazard ratio

hVISA

:   Heterogeneous vancomycin-intermediate *Staphylococcus aureus*

ICU

:   Intensive care unit

IQR

:   Interquartile range

*K. pneumoniae*

:   *Klebsiella pneumoniae*

KPC

:   *Klebsiella pneumoniae* Carbapenemase

LoS

:   Length of stay

MBL

:   Metallo-beta-lactamase

MDR

:   Multidrug resistance

MIC

:   Minimum inhibitory concentration

MLSR

:   Macrolide-lincosamide-streptogramin resistance

MRSA

:   Methicillin resistant *Staphylococcus aureus*

MSSA

:   Methicillin susceptible *Staphylococcus aureus*

NDM-1

:   New Delhi Metallo-beta-lactamase-1

OR

:   Odds ratio

*P. aeruginosa*

:   *Pseudomonas aeruginosa*

PDR

:   Pan drug resistant

res.

:   Resistant

*S. aureus*

:   *Staphylococcus aureus*

sus.

:   Susceptible

TB

:   Tuberculosis

USD

:   United States Dollars

UTI

:   Urinary tract infection

VAP

:   Ventilator associated pneumonia

VRE

:   Vancomycin resistant *Enterococcus*

VSE

:   Vancomycin susceptible *Enterococcus*

XDR

:   Extensively drug resistant
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